Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ADHC ~ It is the goal of the Company to help accelerate the business models for these companies so that they flourish.
Website: ~ http://www.adhcorporation.com ~
News: http://finance.yahoo.com/q/h?s=ADHC+Headlines
Live Chart: http://stockcharts.com/c-sc/sc?s=ADHC&p=w&b=2&g=0&i=p69412508847
$CRWG has been seeing strong growth, with 75% Gross Margin and $691K in Revenue a/o 1/31/2015! The company began to change its tune in 2013 and 2014 after the economic recovery truly began to take hold and capital became easier to raise. In May of 2014, the company sold its flagship PBNation.com forum and other assets to VerticalScope and acquired Plaor - a developer of highly scalable multi-platform games - which generated $690,507 in revenue at an attractive 75% gross margin, as of the three months ended January 31, 2015.
$UWTI Trading Leveraged #Commodities #CrudeOil
$UWTI is looking great! Great trading this week
$EVSV information available on OTCMarkets! http://www.otcmarkets.com/stock/EVSV/profile
$EVSV X-Terminate was originally formulated in 2009 and has been branded successfully in the Tampa Bay community as the “first” pest operation to bring orange oil to this area. The company also handles sub-terranean termites, general home and commercial pest control (GHP) and Lawn & Ornamental nutrition and pest control. Please visit our website of WWW.XTERMINATEINC.COM to learn more.
Hear Ye, Hear Ye:
Praxsyn Corporation (PXYN)--Sued by Former Director Garbino; Serious Allegations.
Interesting allegations in the TPS lawsuit filed in Orange County, California Superior Court on April 6, 2015, case number 30-2015-00781113-CU-BC-CJC . John Shebanow is alleged to be the largest shareholder of Praxsyn and the one in control of the company. The lawsuit has an attachment to it which is Garbino's resignation letter to Praxsyn. In his letter, Garbino lays out a host of issues related to his resignation. Praxsyn was required under law to file that letter with the 8-K announcing his resignation. Praxsyn did not. Instead, Praxsyn lied and said that Garbino resigned due to a conflict of interest. (Paragraph 44 of the Complaint) Total damages sought "in excess of $75 million." Furthermore, it is contended that TPS's Series D Preferred was not cancelled and is still owned by TPS. We see from the register of actions in the case that Praxsyn filed an ant-slapp motion and that it is scheduled for August. Seems to be completely meritless defense. The demurrer filed, that the action is precluded by the suit against TPS, is kind of silly. The cases are going to be joined. Very, very serious allegations and look credible.
$PXYN.022-Why-Praxsyn-may-TRIPLE! Seeking-Alpha-Article-LINK...
http://seekingalpha.com/instablog/9330801-drugdoctor/4056376-pxyn-022-praxsyn-pharma-corp-net-profits-why-a-2-cent-stock-is-likely-to-triple
$PXYN.022 Praxsyn-Pharma-Corp-NET PROFITS-Why A 2 Cent Stock Is Likely To Triple
Jun 2, 2015 8:01 AM | about stocks: PXYN
I have been investing in large cap stocks, mutual funds, and penny stocks for over 30 years and have had much success with all 3 categories. My current strategy is to find penny stocks that triple or more in price, take my initial investment back out, and if the stock continues to rise, to take profits on the way up and add to my large cap and mutual fund positions. My largest single stock holding is Facebook, which I started buying at $55 per share. With that history, let's look at what I believe is the best little penny stock company on the OTC market at this time.
Praxsyn Corp, (OTCBB PXYN.022) is a Compounding Prescription Pharmacy company, which compounds pain relieving medications for patients specific to a Doctor's written prescription. These medications are absorbed through the skin very near the site of pain and/or inflammation, eliminating many of the potential side effects of oral systemic absorption, such as drowsiness or stomach irritation/nausea.
The compounds Praxsyn markets are often a combination of medications which are not available on the market by the large Pharmaceutical Manufacturers, thus offering a unique treatment that can be modified exactly to treat many various conditions.
Since the medications Praxsyn is marketing are not addictive, the insurance companies are happy to pay for them, vs expensive addictive narcotic pain killers, which may cause many more claims as drug seeking behavior often results in many more claims in a work comp case than the underlying condition should have required.
The first quarter 2015 results are out for PXYN and they are 1.28 million dollars NET PROFITS - on Net Revenues of 14 million dollars. $500,000 dollars of those profits were reserved for taxes. The company has recently given raises to employees in preparation for Nationwide expansion, and already is doing business in 15 of the 28 USA states in which they have obtained Pharmacy Licenses.
Praxsyn-Announces-Over-$4-Million-in-PPO-Approved-Claims-for-February-of 2015
IRVINE, Calif., March 3, 2015 -- Praxsyn Corporation (OTCQB:PXYN (link is external)) announces that its wholly owned subsidiary, Mesa Pharmacy Inc. (Mesa), has final committed amounts in excess of $4 million for approved preferred provider organization (NYSE:PPO) claims dating from February 1, 2015 through February 28, 2015 from 15 of its 28 licensed states across the country. The commitment of these claims has been accomplished through its previously announced marketing agreement with NHS Pharma, Inc. Marketing and billing costs are still applicable at industry standards of 55 percent of the total amount billed.
"The benefit of PPO is that every claim is approved at the billed amount and at the point of service," said Edward Kurtz, Chief Executive Officer, Praxsyn Corporation. "Insurance companies are committed to pay the total amount billed within 30-90 days of the prescription being filled. This eliminates the need for Mesa to finance their PPO claims."
Due to the faster processing of PPO claims, Mesa expects to have more cash on hand in order to pay down debt and continue growing the business. "Reinvesting cash into the business is part of our overall strategy of increasing value to our shareholders," said Bob Crowson, Controller, Praxsyn Corporation.
http://praxsyn.com/press_releases/praxsyn-announces-over-4-million-ppo-approved-claims-february-2015
The SEC 10Q filing for period ending March 31st, 2015 shows that Praxsyn generates 90% Gross Profit margins and had Operating Profits of 5 million dollars. There still are interest charges and debts left over from the shell company they used for the merger, but they are rapidly reducing those charges, and future results are expected to be even better.
Praxsyn also disclosed they now have 75 employees, have doubled production capacity, and are entering a period of Nationwide expansion and growth.
Praxsyn has recently entered the PPO market for it's compounded prescriptions, which will give PXYN much faster payments and will reduce processing and collection costs, much more than the California Workers Comp business, which it is still actively pursuing, but pays much slower that a PPO adjudicated claim.
All the above information can be seen in the SEC 10Q filing, which I encourage any interested investor to read. (OTCPK:LINK)
ih.advfn.com/p.php?pid=nmona&article...
Also of note, on the balance sheet, there are 12 million dollars in accounts receivable.
When scanning the financials, you can see that in 2014, the company posted losses for the first 2 quarters, as they cleaned up the books, paid down debt, and had other charges. The turnaround for PXYN has been remarkable, as Q1 2015 demonstrates.
http://finance.yahoo.com/q/is?s=pxyn
So why is the stock hovering near its yearly low with such great results posted, one may ask?
The answer is, that Praxsyn is just unknown to the financial community. As a "penny stock" a lot of investors will not even consider it, and there has been some controversy generated by PXYN changing marketing vendors from a company called TPS, to NHS Pharma Sales and Products for Doctors.
TPS was the vendor in 2014 and generated over 100 million dollars in Gross Revenue Billing claims, however, many of these claims turned out to be non-qualified claims and are now the subject of a lawsuit that Praxsyn has against it's previous exclusive vendor.
TPS filed a counter suit against Praxsyn which is addressed in the 10Q SEC filing by management. "Praxsyn counsel believes this lawsuit to be largely baseless"
Trestles Pain Specialists
On March 11, 2015, we filed a lawsuit in the Superior Court of California, Orange County (Case No. 30-2015-00776389) against Trestles Pain Specialists, LLC ("TPS"), John Garbino and David Fish. We first allege that TPS breached the terms of the consulting services agreement due to lack of performance by TPS of the agreed upon services. Second, we allege that we were fraudulently induced into entering into the consulting services agreement due to the misrepresentation made by Mr. Garbino that Mr. Fish, who has some unsettling issues that were of concern to us, was not an owner of TPS. Had we known that Mr. Fish did have a stake in TPS, we would not have entered into the consulting services agreement. We allege additional causes of action for unfair business practices, breach of good faith and fair dealing, intentional interference of contract, intentional interference with prospective advantage, and conspiracy to defraud. In addition to damages of over $1,500,000 we are seeking rescission of the consulting services agreement so that all moneys paid would be refunded to us, which exceed $17,000,000. On April 30, 2015 we amended the complaint to include actions against Ray Riley for tortious interference of contract.
TPS v. Mesa, Praxsyn, et al
TPS filed a lawsuit against Mesa/Praxsyn and a host of other codefendants in April 2015 (30-2015-00781113-CU-BC-CJC) alleging 23 various causes of action. Mesa/Praxsyn has demurred as many of the causes of action should be stayed until the outcome of our action against TPS (described above) is determined. They have sued vendors, shareholders, officers and various individuals based on an iteration of facts that are largely disputed by Praxsyn and all co-defendants. Praxsyn counsel believes this lawsuit to be largely baseless due to various writings and releases signed by John Garbino, a former director of our Company. Discovery on this lawsuit is on hold until late August due to an Anti Slapp motion filed against TPS. We do not believe there is any new exposure to Praxsyn under this suit, as the underlying claims are already reserved for in the Praxsyn V. Trestles Pain Specialists suit.
Penny stocks are discussed widely on various message boards and blogs, and it is believed that there has been a coordinated effort by some of the TPS associates to try to damage PXYN with a smear campaign on the message boards, as warnings that PXYN wouldn't report any revenue because TPS was gone, and many other scare tactics have been posted... As has been demonstrated, the reality is, that PXYN is doing fine now, is rapidly growing and expanding, has achieved licenses to do business in 28 USA states, vs 1 in 2014, and has 2 very well respected and established marketing companies hired and growing the business already in 15 states as of last report, and we suspect, many more by now. Of note also, is that Praxsyn also hired a very well known and respected California talk show host and Compounding Pharmacy expert Pharmacist as their PIC (Pharmacist in Charge). We expect to hear about some exciting NEW PRODUCT launches in the near future as a result of this hire.
PRAXSYN ANNOUNCES NEW PHARMACIST IN CHARGE FOR MESA PHARMACY
IRVINE, Calif., March 9, 2015 -- Praxsyn Corporation's (OTCQB: PXYN) wholly owned subsidiary, Mesa Pharmacy Inc. (Mesa), announced today that, as of February 12, 2015, Dr. Amy Lee (Hawkins) Summers, Pharm, D., has joined the company as its new pharmacist in charge (NYSEARCA:PIC) and director of pharmacy.
Dr. Summers is a compounding expert and a bioidentical hormone specialist, who, since 2007, has been a compounding pharmacist and has invented numerous proprietary prescription compounds to meet the unique needs of patients. She has also developed ground-breaking pharmacy policies and procedures that have set new quality standards in the practice of compounding.
"We are thrilled to introduce Dr. Summers as our new PIC and look forward to experiencing her creativity and seeing her inventive ideas come to fruition at Mesa," said Kelly Reynolds, Chief Executive Officer, Mesa Pharmacy.
"It is exciting to join a company that is expanding at such an impressive pace," said Dr. Summers, Pharmacist in Charge, Director of Pharmacy, Mesa Pharmacy. "Mesa's dedication of offering a healthier alternative to narcotic pain medication aligns perfectly with my own goals as a pharmacist." Dr. Summers enjoys working with patients to improve their health and partnering with physicians on ways to be creative in an ever stringent regulatory and economic environment.
Early in her career, Dr. Summers developed an interest in how the human body works and graduated with a bachelor's degree in biochemistry. She then received her doctor of pharmacy degree from the top pharmacy school in the nation, the University of California San Francisco, where she excelled in topics including pharmacology and biopharmaceutics. Dr. Summers has completed extensive training and continuing education in compounding pharmaceuticals and specializes in bioidentical hormone replacement therapy, functional medicine, detoxification, sterile and non-sterile compounds as well as nutrition.
Dr. Summers is a former talk radio personality on KRSO 1350 AM in Santa Rosa, California, and also authored the nationally acclaimed book, What You Must Know about Bioidentical Hormone Replacement Therapy. She is a board certified pharmacist in California, Nevada and Mississippi, and is a member of the Anti-Aging Medicine and the Institute for Integrative Medicine.
So with all the positive accomplishments of this new little company in just over 1 year as a public company, and the remarkable progress made in replacing their marketing company with other marketing companies, along with the hiring of Dr. Summers, and the potential for major NEW PRODUCT ANNOUNCEMENTS, the rest of 2015 looks bright for Praxsyn. With the stock hovering near 52 week lows, it could be a very nice speculative investment or trade for the rest of the year.
Disclosure: The author is long PXYN.
Additional disclosure: microcap
Themes: Pharmacy microcap Stocks: PXYN
$VMRI Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=VMRI+Profile
$CYBG Great research can be found here http://www.ddnotesmaker.com/index.php?ticker=cybg
$DRNE On Watch For A Move #NYSE
$GTMM On Watch For A Move #NASDAQ
VMRI Updated Barchart (barchart.com): http://www.barchart.com/quotes/stocks/VMRI
$CYBG 2014 Annual Report here:
http://ir.cybergypartners.com/annual-reports
$XFUL XPetroleum™ should never be confused with more problematic, but popular, Biofuel types such as ethanol and biodiesel. Both ethanol and biodiesel suffer from the fact that – unlike XPetroleum™ – they are not easily integrated with the petrofuels distribution system.
Check out the $XFUL website here: http://www.xfuels.com/
$XFUL today announced the completion of the purchase of XFuels, LLC, for 500,000 shares of the company's capital stock. This acquisition positions the combined company as a clear leader in carbon-neutral energy solutions, as well as providing water and food technologies specifically designed to improve life on our planet.
http://finance.yahoo.com/news/xfuels-llc-acquired-converde-energy-122000178.html
$XFUL ~ Daily Chart Consolidation >>
$XFUL News: http://finance.yahoo.com/q/h?s=XFUL+Headlines
$XFUL Live Chart: http://stockcharts.com/c-sc/sc?s=XFUL&p=D&b=1&g=0&i=p69412508847
$DRNE Ready To Move Again! #NASDAQ
$VMRI ~ Industries looking to fly Drones and why Investors will take Advantage ~ http://valmie.com/industries.html
SIGL ~ Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SIGL+Key+Statistics
$MVTG update with Stanford University backing the MVTG fuel cell advantage!!!!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114006330
And MVTG broke out over resistance at .20/.21 and is primed for huge run back to at least the .75 highs of last year as the two showcase investor work shop events unfold this week and next week. MVTG will showcase the worlds first MVTG manufactured Formic acid powered (made from waste CO2 with the Alstom-GE backed ERC-reactor that converts CO2 and solar power into renewable fuel), MVTG-MRFC fuel cell powered vehicle, with fuel cells that cost 1/5th of anything on the market.
INOH on the verge of a breakout
http://www.officedepot.com/a/products/477614/Aquaboy-Atmospheric-Water-Generator-Grey/
$EVSV Mr. Trina is a native mid-westerner born in Indiana but raised in the Chicago area. Upon graduation from the University of South Florida with an accounting degree in 1985 immediately got into the stock brokerage business. From 1986-2007 he worked at various regional brokerage firms in the capacities of sales, management and investment banking. Up until 2007 he held his securities licenses series 7 and 24 and insurance licenses for fixed and variable products and was quite successful in estate planning.
$VMRI Valmie is in the process of testing its V-1 Drone prototype, which will feature a higher level of agility than many other models. Valmie's UAV will be paired with its revolutionary Software as a Service (SaaS) AIMD (Autonomous Intelligence for Mobile Devices) Platform - also in development - a powerful and feature-rich modular program for enhancing the connection between many types of unmanned vehicles, including drones, and other smart systems.
The $MYOS strategy is to understand the complex genetic and molecular pathways regulating muscle mass and function, as well as other disease mechanisms. Understanding the impact of complex regulatory pathways which act to build and maintain healthy lean muscle is central to the company’s pioneering biotherapeutic discovery science. This research is the foundation of their bionutritional product development. MYOS is developing nutritional products that target specific mechanisms to promote health in ways that cannot be met by other treatments, diets or lifestyle changes.
$EVSV X-Terminate was originally formulated in 2009 and has been branded successfully in the Tampa Bay community as the “first” pest operation to bring orange oil to this area. The company also handles sub-terranean termites, general home and commercial pest control (GHP) and Lawn & Ornamental nutrition and pest control. Please visit our website of WWW.XTERMINATEINC.COM to learn more.
$MYOS is seeing improving investor sentiment. Take a look at what traders have to say on Penny Stock Tweets here: http://www.pennystocktweets.com/stocks/profile/MYOS
$EVSV As of June 1, 2013 Enviro-Serv, Inc. successfully acquired X-Terminate Pest Management Inc. X-Terminate is a full service and fully licensed florida pest control operation based in St. Petersburg Florida. The company specializes in utilizing orange oil and other low impact product to eradicate dry wood termites however does hold the license to fumigate properties when deemed necessary to do so.
$VMRI As a result of the exploding growth of this industry, a void exists between hobby and military level drones. Valmie helps fill this gap to meet specific commercial mission requirements. Drone systems are now available – and affordable – as a result of evolving micro-controller technologies and the universality of inexpensive, accurate sensors.
$EVSV These warm climate companies create an ongoing cash flow thru maintenance contracts with small to medium size companies. A few examples of our target clientele for maintenance contracts are as follows: convenience store chains, office buildings, hospitals and medical complexes, professional office complexes, apartment complexes, condo complexes, to name a few. Thru the ongoing marketing of services in the sectors mentioned, Enviro-Serv plans to expand its contracted maintenance base while maintaining a high quality customer service experience. This strategy will enable Enviro-Serv to build a highly visible brand in this profitable service sector and become synonymous with high quality service.
$MYOS is dedicated to developing innovative products that improve muscle mass, increase mobility and reduce frailty. MYOS is a biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance.
$VMRI Will Boost Search and Rescue Efforts - Signs MOU to Provide Drone Technology:
http://finance.yahoo.com/news/valmie-vmri-boost-search-rescue-113000146.html
$EVSV ~ Enviro Serv, Inc. (OTC: EVSV) is a Tampa based corporation specializing in providing property maintenance services in geographically concentrated warm climate states. Through an aggressive acquisition strategy, the Company is building a portfolio of highly profitable enterprises that offer year round services such as pest control management, lawn and landscaping care, pool maintenance, air conditioning/refrigeration installation and repairs and a host of additional onsite maintenance offerings. Please visit our websites at www.enviro-serv.com and www.xterminateinc.com to learn more.
$EVSV Enviro-Serv Inc.(EVSV) is a Delaware corporation. The Company is building a portfolio of highly profitable property maintenance services companies that are geographically concentrated in warm climate states.
Put $GTMM On Radar $AAPL http://goo.gl/Vb8wAi
$EVSV These companies provide year round services including pest management, lawn and ornamental care, pool maintenance, air conditioning/refrigeration engineering and a host of additional on site maintenance offerings.
$EVSV These warm climate companies create an ongoing cash flow thru maintenance contracts with small to medium size companies. A few examples of our target clientele for maintenance contracts are as follows: convenience store chains, office buildings, hospitals and medical complexes, professional office complexes, apartment complexes, condo complexes, to name a few. Thru the ongoing marketing of services in the sectors mentioned, Enviro-Serv plans to expand its contracted maintenance base while maintaining a high quality customer service experience. This strategy will enable Enviro-Serv to build a highly visible brand in this profitable service sector and become synonymous with high quality service.
$EVSV also owns X-terminate, visit their website here: http://xterminateinc.com/
$VMRI From transporting critical medical supplies to finding a missing child, drones have the capability to make the world better. This robust technology can also make companies perform better. We invite you to contact us to explore using drones to improve your business.
$EVSV As of June 1, 2013 Enviro-Serv, Inc. successfully acquired X-Terminate Pest Management Inc. X-Terminate is a full service and fully licensed florida pest control operation based in St. Petersburg Florida. The company specializes in utilizing orange oil and other low impact product to eradicate dry wood termites however does hold the license to fumigate properties when deemed necessary to do so.
$VMRI "As an AUVSI member, Valmie will not only recognize the work of pioneering colleagues but also help influence the policies that address the industry's most pressing concerns," said Gerald B. Hammack, President and CEO of Valmie. "As we put our V-1 Drone through its paces, we look forward to helping make important advancements in the industry and cultivating a strong and lasting relationship with AUVSI."
$WPRT - SLAP THE ASK! #NATGAS #FLEET
$SINX: Fracking water recycling plant: Joint Venture to Construct and Operate Brine and Water Reclamation Facility in Montana.
Could be used by Big Oil like Exxon, etc
bullish
bullish divergence breakout
## source: finance.yahoo.com
Tue, 03 Jun 2014 13:00:00 GMT ~ Sionix Corporation Announces Signing Letter of Intent for Formation of Joint Venture to Construct and Operate Brine and Water Reclamation Facility in Montana
[Marketwired] - Sionix Corporation reported today that it has signed a Letter of Intent to form a 50-50 Joint Venture with BR Investments, LLC, an affiliate of The Prime Group, Inc. The Letter of Intent provides for the ...
read full: http://finance.yahoo.com/news/sionix-corporation-announces-signing-letter-130000604.html
z
$SINX: Fracking water recycling plant: Joint Venture to Construct and Operate Brine and Water Reclamation Facility in Montana.
Could be used by Big Oil like Exxon, etc
bullish
bullish divergence breakout
## source: finance.yahoo.com
Tue, 03 Jun 2014 13:00:00 GMT ~ Sionix Corporation Announces Signing Letter of Intent for Formation of Joint Venture to Construct and Operate Brine and Water Reclamation Facility in Montana
[Marketwired] - Sionix Corporation reported today that it has signed a Letter of Intent to form a 50-50 Joint Venture with BR Investments, LLC, an affiliate of The Prime Group, Inc. The Letter of Intent provides for the ...
read full: http://finance.yahoo.com/news/sionix-corporation-announces-signing-letter-130000604.html
z
Here is what $MVTG has completed versus what MVTG has walked away from and thus has not completed. Being a day late on an update on an ongoing project does not count as failed to complete, only delayed a day!!!
A company in the start up stages should be looked at and invested in for it has completed since the IPO (positive side), not just for it is still on its to do list (possibly negative).
Off the top of my head, I see these (quit a few in fact) on the completed list,
Acquiring 2 international patent applications from Professor Colin Oloman and UBC University.
Acquiring low share dilution funding for 8 years during the toughest fund raising times since the great depression.
NO R/S
NO R/M
No sell out to 3M for chump change of $5 Mil dollars in 2009
OS under 71 million, AS 100 still 100 Mil since the IPO.
CEO investing his own cash (unsecured and interest free) at critical times to MVTG to avoid low share price dilution, and taking IOUs for his pay check which is about 15% of what the average CEO charges.
6 Issued international patents recently won!!!!!
% more applied for and 2 of them just published and readable online as of last week!!!
Several successful R&D projects including the major one in 2012 (that produced a 10X improvement in efficiency and 4x increase in product purity), and the one in 2013 on the new fuel cells, and the huge 2 stage R&D project with Alstom which was also a huge success (otherwise Alstom would not have funded the 3rd stage weeks ago).
About 6-10 R&D projects completed that are now in published highly regarded science and technical journal articles led by major University Professors at about 6 major international Universities that teamed up with MVTG to evaluate the MVTG ERC and MRFC fuel cells and fuels.
http://mantraenergy.com/mantra-energy/technology/publications/
Acquiring major, deep pocket, international partners and their funding from Alstom GE, LaFarge, ...
http://mantraenergy.com/partners/
Major web site upgrade projects done
New investor pdfs created and passed out to major investor groups.
http://mantraenergy.com/investors/investor-resources/
New MVTG R&D and product development and fabrication and testing lab created and equipped in record time last summer.
New lab staffed with top notch people whose salaries are about 90% paid for by Canadian Gov agency grants and paid for hire by Alstom, the stage 3 project just started.
About $750,000 in Canadian Agency grants awarded to help develop, and market MVTG ERC and MRFC fuel and fuel cell technology in recent months.
There is no other OTC stock in existence that has completed so much, in so little time with so little money and for so few shares. Nor is there a better value and risk stock in OTC than MVTG, that is so undervalued with such a major fantastic track record to buy and invest in.
Investing is a risky business!!!! The trick is to find the ones that get things done, and build value. MVTG reached a peak market cap of about 50 million dollars last year, compared to an all time low of under 1 million in 2011 Dec, and compared to the 3M offer in 2009 of 5 million before MVTG had any partners or issued patents.
Major coup of securing a well credentialed ex-VP of Prudential Securities as a new independent director of MVTG.
The MVTG 3D printer work has been a huge success, and is likely to lead to new patents and share value that will exceed last years peak market cap all by itself. They used a new 3D printer to print custom parts for a second built in house 3D printer that was used to build custom new generation fuel cell parts, catalyst electrodes that are being patented now!!
Securing a major international M&A experienced law firm as the new MVTG law firm and so on...
Followers
|
382
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
41945
|
Created
|
05/03/11
|
Type
|
Free
|
Moderator QuickDraw007 | |||
Assistants Zardiw Penny Roger$ |
GLER | 240 % Gains |
SHOM | 70% Gains |
VLCO | 276% Gains |
YIPI | 245% Gains |
GLER | 116% Gains |
PHAR | 72% Gains |
GRPS | 63% Gains |
TOFS | 48% Gains |
WTCT | 122% Gains |
EMXC | 357% Gains |
ACGX | 108% Gains |
CYIO | 71% Gains |
EFIR | 100% Gains |
APII | 119% Gains |
ATTD | 101% Gains |
ICNM | 49% Gains |
BMSPF | 66% Gains |
KMAG | 62% Gains |
PVSP | 86% Gains |
GRNE | 66% Gains |
PSRU | 80% Gains |
STHG | 77% Gains |
DIGX | 70% Gains |
VPER | 305% Gains |
SRPX | 43% Gains |
SEEK | 40% Gains |
AXCG | 105% Gains |
TWWI | 100% Gains |
SAVY | 40% Gains |
BWMG | 42% Gains |
LUDG | 40% Gains |
HIMR | 41% Gains |
GROV | 58% Gains |
HIMR | 37% Gains |
AXCG | 88% Gains |
PNGM | 29% Gains |
AXCG | 22% Gains |
WHEN | 100% Gains |
MDFZF | 46% Gains |
QASP | 737% Gains |
YLLC | 58% Gains |
PVSP | 58% Gains |
SEHI | 60% Gains |
LIGA | 28% Gains |
SFAZ | 1133% Gains |
Posts Today
|
0
|
Posts (Total)
|
41945
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |